Co-Diagnostics Inc $ 10.54 0.38 (3.74%)
Warning! GuruFocus has detected 2 Severe warning signs with CODX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Co-Diagnostics Inc () from 2017 to Jan 18 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Co-Diagnostics stock (CODX) PE ratio as of Jan 18 2021 is 11.71. More Details
Co-Diagnostics PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
Co-Diagnostics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:LNTH NAS:SRDX NAS:AXDX OTCPK:GWHP NAS:PACB NAS:VIVO NAS:PSNL NAS:QTNT NAS:CSTL NAS:FLGT NYSE:TMO NYSE:DHR NAS:ILMN XAMS:PHIA XSWX:LONN NAS:DXCM NYSE:IQV NYSE:A NAS:IDXX SHSE:603259
Address 2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.